The Low-Affinity Binding of Second Generation Radiotracers Targeting TSPO is Associated with a Unique Allosteric Binding Site

. 2018 Mar ; 13 (1) : 1-5. [epub] 20170905

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural

Perzistentní odkaz   https://www.medvik.cz/link/pmid28875261

Grantová podpora
P30 MH075673 NIMH NIH HHS - United States
R25 MH080661 NIMH NIH HHS - United States
UL1 TR001079 NCATS NIH HHS - United States
P01MH075673 NIH HHS - United States

Odkazy

PubMed 28875261
PubMed Central PMC5790609
DOI 10.1007/s11481-017-9765-2
PII: 10.1007/s11481-017-9765-2
Knihovny.cz E-zdroje

[11C]-PK11195 (PK11195) has been widely used with positron emission tomography (PET) to assess levels of the translocator protein 18 kDa (TSPO) as a marker of neuroinflammation. Recent ligands, such as [11C]-PBR28 and [11C]-DPA713, have improved signal-to-noise ratio and specificity for TSPO over PK11195. However, these second generation radiotracers exhibit binding differences due to a single polymorphism (rs6971) that leads to three genotypes: C/C, C/T and T/T associated with high, mixed and low binding affinities, respectively. Here we report that [3H]-DPA-713 in the presence of cholesterol or PK11195 has an accelerated dissociation rate from TSPO in platelets isolated from individuals with the T/T genotype. This allosteric interaction was not observed in platelets isolated from individuals with the C/C or C/T genotype. The results provide a molecular rationale for low binding affinity of T/T TSPO and further support the exclusion of these subjects from PET imaging studies using second generation TSPO ligands.

Zobrazit více v PubMed

Chauveau F, Boutin H, Van Camp N, Dolle F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35:2304–2319. doi: 10.1007/s00259-008-0908-9. PubMed DOI

Costa B, Da Pozzo E, Giacomelli C, Barresi E, Taliani S, Da Settimo F, Martini C. TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy. Sci Rep. 2016;6:18164. doi:srep18164 [pii]10.1038/srep18164. PubMed PMC

Coughlin JM, et al. Regional brain distribution of translocator protein using [(11)C]DPA-713 PET in individuals infected with HIV. J Neurovirol. 2014;20:219–232. doi: 10.1007/s13365-014-0239-5. PubMed DOI PMC

Guo Y, et al. Protein structure. Structure and activity of tryptophan-rich TSPO proteins. Science. 2015;347:551–555. doi:347/6221/551[pii]10.1126/science.aaa1534. PubMed PMC

James ML, et al. DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med. 2008;49:814–822. doi:jnumed.107.046151[pii]10.2967/jnumed.107.046151. PubMed

Kreisl WC, et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab. 2013;33:53–58. doi:jcbfm2012131 [pii]10.1038/jcbfm.2012.131. PubMed PMC

Li F, Liu J, Zheng Y, Garavito RM, Ferguson-Miller S. Protein structure. Crystal structures of translocator protein (TSPO) and mutant mimic of a human polymorphism. Science. 2015;347:555–558. doi:347/6221/555[pii]10.1126/science.1260590. PubMed PMC

Limbird LE. Cell Surface Receptors Third. Third. Springer; New York: 2005.

Owen DR, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med. 2011;52:24–32. doi:jnumed.110.079459[pii]10.2967/jnumed.10.079459. PubMed PMC

Owen DR, et al. Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab. 2010;30:1608–1618. doi:jcbfm201063[pii]10/1038/jcbfm.2010.63. PubMed PMC

Owen DR, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32:1–5. doi:jcbfm2011147[pii]10.1038/jcbfm.2011.147. PubMed PMC

Rupprecht R, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010;9:971–988. doi:nrd3295[pii]10.1038/nrd3295. PubMed

Selvaraj V, Stocco DM. The changing landscape in translocator protein (TSPO) function. Trends Endocrinol Metab. 2015;26:341–348. doi:S1043-2760(15)00033-8[pii]10.1016/j.tem.2015.02.007. PubMed PMC

Turkheimer FE, Rizzo G, Bloomfield PS, Howes O, Zanotti-Fregonara P, Bertoldo A, Veronese M. The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans. 2015;43:586–592. doi:BST20150058[pii]10.1042/BST20150058. PubMed PMC

Vivash L, O'Brien TJ. Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases? Journal of Nuclear Medicine. 2016;57:165–168 d. oi:10.2967/jnumed.114.141713. PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace